Peptides as NS3-serine protease inhibitors of hepatitis C virus

Details Peptides as NS3-serine protease inhibitors of hepatitis C virus Peptides as NS3-serine protease inhibitors of hepatitis C virus

2006-03-14

2006-03-14

Weber, Jon (Department: 1653)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S330000, C530S331000

Reexamination Certificate

active

07012066

ABSTRACT:
The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

REFERENCES:
patent: 5162500 (1992-11-01), Takeuchi et al.
patent: 5359138 (1994-10-01), Takeuchi et al.
patent: 5488067 (1996-01-01), Hanson
patent: 5496927 (1996-03-01), Kolb et al.
patent: 5514694 (1996-05-01), Powers et al.
patent: 5633388 (1997-05-01), Diana et al.
patent: 5712145 (1998-01-01), Houghton et al.
patent: 5739002 (1998-04-01), De Francesco et al.
patent: 5763576 (1998-06-01), Powers
patent: 5843450 (1998-12-01), Dawson et al.
patent: 5843752 (1998-12-01), Dasmahapatra et al.
patent: 5849866 (1998-12-01), Kolb et al.
patent: 5854001 (1998-12-01), Casey et al.
patent: 6265380 (2001-07-01), Tung et al.
patent: 2362911 (2000-09-01), None
patent: 0 195 212 (1986-09-01), None
patent: 0 363 284 (1990-04-01), None
patent: 381 216 (1990-08-01), None
patent: 0 423 358 (1991-04-01), None
patent: 0 672 648 (1995-09-01), None
patent: 0 672 648 (1995-09-01), None
patent: 2778406 (1999-11-01), None
patent: 2 338 482 (1998-04-01), None
patent: 4-001140 (1992-01-01), None
patent: 04 149166 (1992-05-01), None
patent: WO 89/04669 (1989-06-01), None
patent: WO-92/11850 (1992-07-01), None
patent: WO-94/00095 (1994-01-01), None
patent: WO-95/33764 (1995-12-01), None
patent: WO-96/40743 (1996-12-01), None
patent: WO-97/06804 (1997-02-01), None
patent: WO-97/31937 (1997-09-01), None
patent: WO 98/07734 (1998-02-01), None
patent: WO-98/12308 (1998-03-01), None
patent: WO-98/13462 (1998-04-01), None
patent: WO-98/14181 (1998-04-01), None
patent: WO 98/17679 (1998-04-01), None
patent: WO 98 17679 (1998-04-01), None
patent: WO 98/22496 (1998-05-01), None
patent: WO-98/29435 (1998-07-01), None
patent: WO-98/37180 (1998-08-01), None
patent: WO-99/07733 (1999-02-01), None
patent: WO 99 07734 (1999-02-01), None
patent: WO-99/64442 (1999-12-01), None
patent: WO00/05245 (2000-02-01), None
patent: WO 00/09543 (2000-02-01), None
patent: WO 00/09558 (2000-02-01), None
patent: WO 00 52032 (2000-09-01), None
patent: WO 01 40262 (2001-06-01), None
patent: WO 01 74768 (2001-10-01), None
patent: WO-02/18369 (2002-03-01), None
Suto M.J., et al: “Peptide Inhibitors of IKB Protease: Modification of the C-termini of Z-LLF-CHO”, Biorganic & Medicinal Chemistry Letters, Oxford, GB, vol. 6, No. 24, Dec. 17, 1996.
Patel, D.V. et al, “Activated Ketone Based Inhibitors of Human Renin”, Journal of Medicinal Chemistry, American Chemical Society, Washington, US, vol. 36, No. 17, Aug. 1, 1993, pp. 2431-2447.
Asano et al, “Novel Retrovirus Protease Inhibitors, RPI-856 A, B, C and D, Produced by Streptomyces Sp. AL-322”, Journal of Antibiotics, Japan Antibiotics Research Association, Tokyo, JP, vol. 47, No. 5, May 1, 1994, pp. 557-565.
Wei Han, et al, “alpha-Ketoamides, alpha-ketoesters and alpha-diketones as HCV NS3 protease inhibitors”,Bioorganic&Medicinal Chemistry Letters,vol. 10, No. 8, (2000), pp. 711-713.
Llinas-Brunet Montse, et al, “Studies on the c-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease”,Bioorganic&Medicinal Chemistry Letters,vol. 8, No. 19, (1998), pp. 2719-2724.
Pizzi, (1994)Proc. Natl. Acad. Sci(USA) 91:888-892.
Failla (1996)folding&Design1:35-42.
Kollykhalov (1994)J. Virol.68:7525-7533.
Komoda (1994)J. Virol.68:7351-7357.
Landro (1997)Biochem36:9340-9348.
Ingallinella (1998)Biochem37:8906-8914.
Llinas-Brunet (1998)Bioorg. Med. Chem. Lett,8:1713-1718.
Martin (1998)Biochem37:11459-11468.
Dimasi (1997)J. Virol.71:7461-7469.
Martin (1997)Protein Eng.10:607-614.
Elzouki (1997)J. Hepat.27:42-48.
Bio World Today9(217):4 (Nov. 10, 1998).
Berenguer (1998)Proc. Assoc. Am. Physicians110(2): 98-112.
Hoofnagle (1997)New England Journal Med.336:347.
Zhang (199)Analytical Biochemistry270:268-275.
Sali (1998)Biochemistry3392-3401.
Barlos (1991)Int. J. Pept. Protein Res513-520.
Holmberg (1979)Acta Chem. Scand.,B33:410-412.
Agrawal(1999)HepatologySupplement to vol. 30 “Development and Characterization of Hepatitis C Virus Serine Protease Cell-based Trans-Cleavage Assay”.
Hughes (1992)Org. Reactions42:335.
Heck (1989)Org. Reactions27:345-390.
Han, (2000)Bioorganic&Medicinal Chemistry Letters 10“α-Ketoamides, α-Ketoesters and α-Kiketones as HCV NS3 Protease Inhibitors” pp. 711-713.
Marchetti(1999)Synlett,vol. S1, “Synthesis of Two Novel Cyclic Biphenyl Ether Analogs of an Inhibitor of HCV NS3 Protease”, pp 1000-1002.
Bartenschlager et al., Substrate Determinants for Cleavage in cis and in trans by the Hepatitis C Virus NS3 Proteinase, Journal of Virology, Jan. 1995, vol. 69, No. 1, pp. 198-205.
Bianchi et al., Synthetic Depsipeptide Substrates for the Assay of Human Hepatitis C Virus Protease, Analytical Bichemistry 237, 239-244 (1996).
Bouffard et al., An in Vitro Assay for Hepatitis C Virus NS3 Serine Proteinase, Virology 209, 52-59 (1995).
Cho et al., Construction of hepatitis C-SIN virus recombinants with replicative dependency on hepatitis C virus serine protease activity, Journal of Virological Methods 65 (1997), 201-207.
D'Souza et al., In vitro cleavage of hepatitis C virus polyprotein substrates by purified recombinant NS3 protease, Journal of General Virology (1995), 76, 1729-1736.
Filocamo et al., Chimeric Sinbis Viruses Dependent on the NS3 Protease of Hepatitis C Virus, Journal of Virology, Feb. 1997, p. 1417-1427.
Hahm et al., Generation of a Novel Poliovirus with a Requirement of Hepatitis C Virus Protease NS3 Activity, Virology 226, 318-326 (1996).
Hamatake et al., Establishment of an in vitro Assay to Characterize Hepatitis C Virus NS3-4A Protease Trans-Processing Activity, Intervirology 1996;39:249-258.
Harbeson et al., Stereospecific Synthesis of Peptidyl a-Keto Amides as Inhibitors of Calpain, J. Med. Chem. 1994, 37, 2918-2929.
Ito et al., Cultivation of hepatitis C virus in primary hepatocyte culture from patients with chronic hepatitis C results in release of high titre infectious virus, J. Gen. Virol May 1996; 77 (Pt5):1043-54.
Lu et al., Poliovirus chimeras replicating under the translational control of genetic elements of hepatitis C virus reveal unusual properties of the internal ribosomal entry site of hepatitis C virus, Proc. Natl. Acad. Sci. USA, vol. 93, pp. 1412-1417, Feb. 1996.
Mizutani et al., Characterization of Hepatitis C Virus Replication in Cloned Cells Obtained from a Human T-Cell Leukemia Virus Type 1-Infected Cell Line, MT-2, Journal of Virology, Oct. 1996, p. 7219-7223.
Mizutani et al., Inhibition of Hepatitis C Virus Replication by Antisense Oligonecleotide in Culture Cells, Biochemical and Biophysical Research Communications, vol. 212, No. 3, 1995, pp. 906-911.
Mizutani et al., Long-Term Human T-Cell Culture System Supporting Hepatitis C Virus Replication, Biochemical and Biophysical Research Communications 227, 822-826 (1996).
Ogilvie et al., Peptidomimetic Inhibitors of the Human Cytomegalovirus Protease, J. Med. Chem., 1997, 40, 4113-4135.
Scarselli et al., GB Virus B and Hepatitis C Virus NS3 Serine Proteases Share Substrate Specificity, Journal of Virology, Jul. 1997, p. 4985-4989.
Schechter et al., On the Size of the Active Site in Proteases, Biochemical and Biophysical Research Communications, vol. 27, No. 2, 1967.
Shimizu et al., Multicycle Infection of Hepatitis C Virus in Cell Culture and Inhibition by Alpha and Beta Interferons, Journal of Virology, Dec. 1994, p. 8406-8408.
Steinkuhler et al., Product Inhibition of the Hepatitis C Virus NS3 Protease, Biochemistry 1998, vol. 37, pp. 8899-8905.
Sudo et al., Establishment of an in vitro assay system for screening hepatitis C virus protease inhibitors using high performance liquid chromatography, Antiviral Research 32 (1996), pp. 9-18.
Takeshita et al., An Enzyme-Linked Immunosorbent Assay for Detecting Proteoly

Affiliated with

Also associated with

Rating

Peptides as NS3-serine protease inhibitors of hepatitis C virus does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptides as NS3-serine protease inhibitors of hepatitis C virus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides as NS3-serine protease inhibitors of hepatitis C virus will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3542686